CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug566 Imatinib tablets Wiki 1.00
drug143 Baricitinib Oral Tablet Wiki 0.71
drug647 Lopinavir/ritonavir Wiki 0.30

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia

In absence of vaccine and medications specifically designed to treat SARS-CoV-2 disease, identifying treatment options is critical at this time to control the disease outbreak. For this, we have designed a phase II trial of efficacy and safety with 3 branches of different combinations of treatment to identify which is the best early treatment option for patients with pneumonia due to SARS-CoV-2 (Covid-19) Identifying treatment options as early as possible is critical to the SARS-CoV-2 outbreak response. Currently, there is no approved vaccine for the disease and the treatments being used are not specifically designed for the SARS-CoV-2 virus, but are different groups of drugs used for other pathologies with mechanisms of action that justify their use because they inhibit entry of the virus into virus cells or proteases. The study aims to compare lopinavir / ritonavir (200 /50), imatinib 400mg, baricitinib 4mg, in combination with hydroxychloroquine 200mg, administered for 7 days in the setting of SARS-CoV-2 pneumonia treatment. Patients who meet inclusion criteria and do not have any exclusion criteria will be randomized to receive open treatment 1:1:1

NCT04346147 COVID-19 Pneumonia Drug: Hidroxicloroquine Drug: Lopinavir/ritonavir Drug: Imatinib tablets Drug: Baricitinib Oral Tablet

Primary Outcomes

Description: time from inclusion to improvement by 2 points on the "seven-category ordinal scale" or high, whichever comes first

Measure: time to clinical improvement

Time: baseline to day 14

Secondary Outcomes

Description: number of serious adverse effects and premature discontinuation of treatment

Measure: Safety of treatments

Time: through study completion, an average of 1 month

Description: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

Measure: Tolerability of treatments

Time: during treatment and up to 30 days after the last treatment dose

Other Outcomes

Description: Possible biomarkers and genetic markers of susceptibility to SARS-CoV-2 using high-performance techniques with serum DNA from the participants

Measure: Biomarkers and genetic markers of susceptibility to SARS-CoV-2

Time: baseline

Related HPO nodes (Using clinical trials)